Tvardi Therapeutics
TVRD
69 hedge funds and large institutions have $4.17M invested in Tvardi Therapeutics in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 34 reducing their positions, and 16 closing their positions.
0.21% less ownership
Funds ownership: 0.9% → 0.69% (-0.21%)
9% less capital invested
Capital invested by funds: $4.56M → $4.17M (-$394K)
13% less funds holding
Funds holding: 79 → 69 (-10)
56% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 16
85% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$30.8K |
| 2 |
Renaissance Technologies
New York
|
+$14.1K |
| 3 |
FWCM
Ferguson Wellman Capital Management
Portland,
Oregon
|
+$11.3K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.7K |
| 5 |
C
Certuity
North Palm Beach,
Florida
|
+$4.13K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
-$268K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$161K |
| 3 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$107K |
| 4 |
Jane Street
New York
|
-$105K |
| 5 |
Goldman Sachs
New York
|
-$101K |
TVRD Hedge Fund Activity: Q3 2024 in Review
69 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q3 2024, worth a combined $4.17M — down 8.6% from $4.56M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of TVRD and 7 opened new positions — a net loss of 9 holders — while 34 trimmed existing stakes and 5 added.
The largest buyer was XTX Topco, opening a new position worth an estimated $30.8K. The largest seller was Disciplined Growth Investors, cutting an estimated $268K.
- 69 institutional investors held Tvardi Therapeutics (TVRD) as of Q3 2024, down from 79 in Q2 2024.
- Funds reported $4.17M of Tvardi Therapeutics stock for Q3 2024, down 8.6% quarter-over-quarter.
- 7 funds opened new Tvardi Therapeutics positions in Q3 2024 and 16 closed out, a net change of -9 holders.
- The largest Tvardi Therapeutics buyer in Q3 2024 was XTX Topco, an estimated $30.8K added.
- The largest Tvardi Therapeutics seller in Q3 2024 was Disciplined Growth Investors, an estimated $268K sold.
Based on aggregated 13F filings for Q3 2024.